SCHEDULE 13D/A: Sarissa Capital Significantly Reduces Stake in Innoviva, Inc. to 8.4%

Sarissa Capital Management LP and its Chief Investment Officer, Alexander J. Denner, have significantly reduced their beneficial ownership in Innoviva, Inc., disposing of over 2 million shares in early March 2025, bringing their stake down to 8.4%.

Summary

• Sarissa Capital Management LP and Alexander J. Denner, collectively the Reporting Persons, have filed Amendment No. 4 to their Schedule 13D regarding Innoviva, Inc. (the "Issuer").
• As of March 7, 2025, the Reporting Persons beneficially own 5,237,161 shares of Innoviva's Common Stock, representing approximately 8.4% of the Issuer's outstanding shares.
• This percentage is based on 62,675,545 shares stated to be outstanding by Innoviva, Inc. as of February 14, 2025, in its Form 10-K filed on February 26, 2025.
• The Sarissa Funds, advised by Sarissa Capital, engaged in significant open market dispositions of Innoviva shares between March 4 and March 7, 2025.
• On March 4, 2025, 151,175 shares were disposed of at a weighted average price of $17.6291 per share, totaling $2,665,078.96.
• On March 5, 2025, 270,374 shares were disposed of at a weighted average price of $17.6279 per share, totaling $4,766,131.23.
• On March 6, 2025, 1,196,746 shares were disposed of at a weighted average price of $17.5177 per share, totaling $20,964,228.74.
• On March 7, 2025, 421,544 shares were disposed of at a weighted average price of $17.6854 per share, totaling $7,455,167.89.
• The total number of shares disposed of across these four days amounts to 2,039,839 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant reduction in stake by a prominent activist investor, which could imply a lack of further catalysts or a change in investment thesis, potentially signaling a less favorable outlook for the company from this investor's perspective.

Negatives

• Sarissa Capital, a notable activist investor, has significantly reduced its stake in Innoviva, Inc., potentially signaling a change in their investment thesis or a lack of further catalysts.
• The disposition of over 2 million shares by a major shareholder could exert downward pressure on Innoviva's stock price.

Risks

• The Reporting Persons explicitly state they "may make additional sales of Common Stock or enter other transactions related to the Issuer's securities," indicating potential for further share dispositions which could negatively impact the stock price.

Future Outlook

The Reporting Persons explicitly state that they may make additional sales of Common Stock or enter into other transactions related to Innoviva's securities in the future.

Industry Context

This filing reflects a significant reduction in stake by an activist investment firm, Sarissa Capital, in a biopharmaceutical company, Innoviva, Inc. Such moves by activist investors can signal a shift in their strategic involvement or a decision to realize gains, which may influence market perception of the company's future direction or valuation.

Stakeholder Impact

• Shareholders: The reduction in stake by a major activist investor could lead to increased selling pressure and potentially a decrease in share price, impacting shareholder value.
• Company Management: May face questions regarding the activist's reduced involvement and its implications for future strategic direction.

Next Steps

• The Reporting Persons undertake to provide, upon request by the Staff of the SEC, full information regarding the number of Shares purchased at each separate price for the disclosed dispositions.

Key Dates

Recommendation

Keywords

Innoviva Inc., Sarissa Capital Management LP, Alexander J. Denner, Schedule 13D, Share disposition, Beneficial ownership, Activist investor, Common Stock, SEC filing